Continued strong sales trend in Europe and North America. Zlatko Rihter appointed President/CEO. July 1-September 30, 2014 * Net sales increased by 4 % to SEK 47 million (45.1). * Operating profit was SEK 7.7 million (10.7). * The operating margin was 16.3 % (23.7). * Profit before tax was SEK 7.9 million (10.4). * Earnings per share were SEK 0.20 (0.33). * Sales start of two new products; CellaVision®DM9600 and CellaVision®Advanced RBC Application. January 1-September 30, 2014 * Net sales increased by 26 % to SEK 144.4 million (115). * Operating profit increased to SEK 26 million (9.6). * The operating margin increased to 18 % (8.4). * Profit before tax increased to SEK 26.8 million (8.4). * Earnings per share increased to SEK 0.83 (0.26). Significant events after the close of the quarter * Zlakto Rihter was appointed as President/CEO, and starts no later than on February the 1st , 2015. * Sysmex DI-60 and CellaVision®DM1200 approved by the CFDA to be sold in China. * VP Engineering appointed on November 1st, 2014. CEO's comments I'm pleased to see the positive sales trend we have seen since autumn last year is continuing. Sales in the quarter were SEK 47 million, with sales growth of 4 per cent and operating margin of 16.3 per cent. Developments in North America and EMEA lie behind the sales growth and for the first three quarters of the year we report growth of 26 per cent with an operating margin of 18 per cent. At the same time as we have had a good sales trend the work of sound cost control has continued. This contributes to our generating a strong cash flow from operating activities of more than SEK 13 million during the quarter. The sales start for the new product CellaVision®DM9600, replacing the CellaVision®DM96, exceeded expectations even though some initial slowness was noted. Our new software, CellaVision®Advanced RBC Application, was launched in parallel, with the first order going to a Canadian customer. Much work still remains with both products' registration and market preparation. As our new products are fully introduced we will be able to further strengthen our position in the market. Sales to the North American market and Europe make up 91 per cent of total sales for the quarter. The Asian market continued at a lower level than the previous year, largely due to the fact that marketing approval required for new products had not yet been granted in China. After the close of the quarter, however, both Sysmex DI-60 and CellaVision®DM1200 received this approval, which provides the conditions for the growth we see before us in China and other countries in the region. During the quarter a technical pre-study was started to evaluate the new technology platform acquired in the previous quarter. The pre-study is expected to be completed by the end of the year and the long-term ambition with this platform is to develop new products for laboratories that are smaller than those that have made up our target market to date. With three quarters behind us we are proud to deliver the strongest financial performance ever in the history of the company. Zlatko Rihter has been appointed President/CEO, starting on February the 1st 2015, and I will leave my position as President/CEO of CellaVision on the last day of December. It has been a fantastic journey that I have participated in - from a development project to a global company with products in some 50 countries. I want to thank all employees, shareholders and partners for entrusting the leadership of CellaVision to me during my 16 years as President/CEO. At the same time I wish Zlatko Rihter and CellaVision much continued success! Yvonne Mårtensson, President and Chief Executive Officer Key Ratios +----------------------------------------------------------------+ | Jul-Sep Jul-Sep Jan-Sep Jan-Sep Jan-Dec| |(MSEK) 2014 2013 2014 2013 2013| +----------------------------------------------------------------+ |Net sales 47.0 45.1 144.4 115.0 179.9| +----------------------------------------------------------------+ |Gross profit 30.4 27.5 94.6 72.8 112.6| +----------------------------------------------------------------+ |Operating profit 7.7 10.7 26.0 9.6 25.9| +----------------------------------------------------------------+ |Operating margin, % 16.3 23.7 18.0 8.4 14.4| +----------------------------------------------------------------+ |Profit/loss before tax 7.9 10.4 26.8 8.4 24.7| +----------------------------------------------------------------+ |Cash flow for the period 12.3 1.5 0.6 -3.6 11.6| +----------------------------------------------------------------+ Questions concerning the report can be addressed to: Yvonne Mårtensson, President/CEO, CellaVision AB Tel: 0708-33 77 82. E-mail: yvonne.martensson@cellavision.se Magnus Blixt, CFO, CellaVision AB Tel: 0708-33 81 68. E-mail: magnus.blixt@cellavision.se [HUG#1868620]
CellaVision AB: Interim Report January-September 2014
Top 10 Most Recent News Articles
Thanksgiving Dog Safety Is a Pet Care Reality Check
A crowded Thanksgiving kitchen can turn a well-behaved dog into a scavenger with lousy odds. Camp Bow Wow’s holiday guidance is not pretending the meal itself is the problem; the trouble is that a house full of distracted people, rich food and unsecured trash creates a pile of easy mistakes. For pet owners, that is a fair reminder. For anybody watching the pet-care...
Continue Reading
Peptide Labels Cannot Substitute for Clinical Care
A Label Is Not a Care Plan Those three little words, research use only, carry far more weight than a flashy product page would have people believe. The HelloNation article featuring wellness expert Andres Giraldo makes a plain but necessary distinction: a research-use-only, or RUO, label does not turn a peptide into prescribed treatment, and it sure does not establish...
Continue Reading
Washington-to-Asia Advisory Deal Targets Policy Risk
Policy bottlenecks are becoming a cost center across Southeast Asia. That is the plain-English backdrop for the strategic partnership announced November 18, 2026, by Beacon Global Strategies and Vriens & Partners. Neither firm is selling a factory, a chip design, or a new energy project. They are selling something companies increasingly cannot afford to improvise: a...
Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027
New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...
Continue Reading
Tactical Tomahawk Motor Deal Puts Propulsion in Focus
A missile program lives or dies on unglamorous hardware, and solid rocket motors are about as unglamorous as it gets until somebody cannot build enough of them. Raytheon has awarded Ursa Major and Avio USA a joint contract to develop solid rocket motors for the U.S. Navy’s Tactical Tomahawk missile program. That is the whole headline, and it matters more than the thin...
Continue Reading
Insider Risk Makes Human Judgment a Security Priority
A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...
Continue Reading
Google Search Data Sharing Faces a Privacy Reality Check
Search queries are messy little confessions, and that is exactly why this case deserves more than a bureaucratic shrug. Woodway Assurance's independent assessment says Google's search-query data could be treated as anonymized for sharing under the Digital Markets Act, but only if the European Commission tightens parts of its July 2026 framework. That is not a clean bill...
Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal
Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...
Continue Reading
A Decade of Giving: Light the World Initiative's Impact
The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...
Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem
Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...
Continue ReadingTop 5 Most Recently Viewed Articles
Bioretec's Innovative Annual Report Showcases New Progress
Bioretec Ltd's Annual Report Overview Bioretec Ltd has recently published its annual report for 2024, offering insights into the company's growth and achievements over the past year. This report showcases the advancements made in biodegradable orthopedic implants, positioning the company at the forefront of innovative healthcare solutions. Company Highlights Bioretec...
Continue Reading
Market Overview: Asia Stocks See Fluctuations Amid Election Fears
Market Dynamics in Asia: A Closer Look In recent trading sessions, Asian stocks demonstrated muted movements in response to an absence of compelling trading signals, while Japanese shares experienced a notable decline driven by impending democratic choices. Investors are particularly focused on the Japanese electoral scene, which is expected to significantly influence...
Continue Reading
TScan Therapeutics Secures $52.5 Million Loan to Support Growth
TScan Therapeutics Secures $52.5 Million Loan from Silicon Valley Bank WALTHAM, Mass. — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company dedicated to developing innovative therapies for cancer treatment, has announced an exciting milestone. The company has entered into a term loan facility with Silicon Valley Bank (SVB) that offers up to...
Continue Reading
Celebrating Four Years of SpaceX's Starlink Internet Service
Four Years of Starlink Connectivity Four years ago, SpaceX, under the visionary leadership of Elon Musk, began its journey in satellite internet services by activating Starlink for its first paying customer. This significant milestone was established on a date that marks the beginning of a transformative era for internet connectivity. Impact of Starlink on Global Internet...
Continue Reading
AllenComm Receives Esteemed Recognition in eLearning Field
AllenComm Earns Top Honor for eLearning Localization AllenComm, a prominent player in the realm of innovative learning experiences, has recently been recognized as one of the Top Content Providers for eLearning Localization by a well-regarded industry source. This accolade reflects the company's dedication to delivering high-quality, effective educational solutions that...
Continue Reading